来源：科技日报 ◎本报记者 雍 黎 通讯员 黄琪奥 王梦茹 随着医学技术的发展，以CAR-T疗法为代表的免疫治疗受到越来越多学者的关注，也为广大癌症患者带 来了福音。 时雨告诉记者，除了能改善肿瘤微环境外，CAR-M疗法还具备以下优势。"首先，由于嵌合抗原受体巨 噬细胞能感应到肿瘤细胞发出的'信号'，因此其能更准确地找到肿瘤细胞，对其进行精准打击。其次， 嵌合抗原受体巨噬细胞引发严重细胞因子释放综合征（即一种过度激烈的免疫反应）的风险相对较低， 副作用较小，安全性更高，能在精准打击肿瘤细胞的同时，减少对人体的伤害。"时雨说。 "CAR-M与CAR-T疗法虽在原理上相似，但它们攻击肿瘤的方式却各有千秋。"时雨说，CAR-T疗法主 要通过细胞毒作用精准"毒"死肿瘤细胞，而CAR-M疗法则是通过浸润实体瘤组织，来"吃"掉肿瘤细 胞。 深入研究弥补技术缺陷 记者了解到，虽然CAR-M疗法具备诸多优势，但临床及临床前研究也表明，该疗法在临床中应用，除 面临嵌合抗原受体巨噬细胞获取、培养及规模化制备困难、成本较高等问题外，还受到嵌合抗原受体巨 噬细胞在肿瘤组织中的存活时间尚未明确、被"同化"风险是否存在尚不明确等因素制约 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 嵌合抗原受体自然杀伤 （CAR-NK） 细胞是免疫疗法中很有前景的 CAR-T 细胞替代品。在临床试验中， 高剂量和多次输注 CAR-NK 细胞对于维持治疗效果至关重要，因此，需要高效的方法来大规模生成 CAR- NK 细胞。 2025 年 10 月 7 日， 中国科学院动物研究所 王金勇 研究员 、 张梦云 副研究员及 中国医学科学院血液 病医院 （中国医学科学院血液学研究所） 竺晓凡 主任医师， 在 Nature 子刊 Nature Biomedical Engineering 上发表了题为 ： Large-scale generation of iNK and CAR-iNK cells from CD34+ haematopoietic stem and progenitor cells for adoptive immunotherapy 的研究论文。 该研究开发了一种从 脐带血 来源的 CD34 + 造血干细胞/祖细胞 （CD34 + HSPC） 中大规模生成 iNK 细 胞 和 CAR-iNK 细胞 用于癌症免疫治疗的新策略。 关键突破与优势在于—— 在这 ...

Core Viewpoint - AIM ImmunoTech Inc. has received a patent from the Japan Patent Office for the use of Ampligen in combination with checkpoint inhibitors for cancer treatment, enhancing its international market protection and potential for revenue growth [1][2]. Group 1: Patent and Market Implications - The Japan patent strengthens AIM's intellectual property portfolio in a significant oncology market, expiring on December 20, 2039, and enhances exclusivity for combination therapies targeting high-need cancer indications [2][4]. - The patent claims cover a wide range of cancer types, including pancreatic, skin, colorectal, ovarian, melanoma, breast, head and neck, bladder, renal cell carcinoma, and lung cancer, along with specific dosing regimens and administration routes [3]. Group 2: Clinical Development and Collaborations - AIM is advancing its clinical pipeline with Ampligen in combination with AstraZeneca's durvalumab for metastatic pancreatic cancer, showing promising results in Progression-Free Survival and Overall Survival [5]. - A Phase 2 study with Merck Sharp & Dohme LLC combining Ampligen with Keytruda for advanced recurrent ovarian cancer has been completed, with final data expected soon [6]. Group 3: Company Overview - AIM ImmunoTech Inc. focuses on developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen being a first-in-class investigational drug that acts as a TLR3 agonist [7].

据介绍，邻近标记技术是一种强大的"分子地图"绘制技术，能在细胞的特定位置对周边环境进行催化标 记。利用这一技术原理开发的"纳米标记机器人"，可搭载识别癌细胞的抗体或配体，通过血液循环富集 在癌细胞的表面，再通过深红光或超声波下达指令，就可以给癌细胞打上清晰的标记，成为"人造靶 标"。 目前，该研究在实验小鼠肿瘤模型和体外临床肿瘤样本中均取得良好疗效，有望为开发更智能、更高效 的下一代免疫疗法开辟全新的道路。 （文章来源：人民日报） 据新华社电 （记者张建松）在癌症的免疫治疗中，如何精准识别癌细胞？中国科学院分子细胞科学卓 越创新中心韩硕研究团队将化学生物学研究中的邻近标记技术应用于疾病治疗，通过构建一种深红光或 超声波响应的工程化纳米酶，成功开发出可对癌细胞精准识别的"纳米标记机器人"。 国际学术期刊《自然》于9月10日在线发表了相关研究论文。 ...

Core Viewpoint - The research team from the Chinese Academy of Sciences has developed a "nano-marking robot" that can precisely identify cancer cells using a novel chemical biology technique, which may lead to more effective cancer immunotherapy [4][5]. Group 1: Technology and Mechanism - The "nano-marking robot" utilizes proximity labeling technology to create a "molecular map" that catalyzes marking in specific cellular locations [4]. - This robot can carry antibodies or ligands that accumulate on the surface of cancer cells through blood circulation, allowing for clear marking under deep red light or ultrasound [4][5]. Group 2: Research Outcomes - In experiments with mouse tumor models and clinical tumor samples, the technology demonstrated promising efficacy, indicating potential for developing smarter and more efficient next-generation immunotherapies [5]. - The study received funding from various national and local scientific programs, highlighting its significance and support within the scientific community [5].

Group 1 - Chinese researchers have developed a "nano-marking robot" for cancer immunotherapy, utilizing proximity labeling technology to create engineered nanoenzymes that can accurately identify cancer cells, showing promising results in mouse tumor models and clinical samples [1] - The research aims to pave the way for smarter and more efficient next-generation immunotherapies by addressing the challenge of cancer cells disguising themselves and providing insufficient natural signals for immune cells to attack [1] Group 2 - Yushutech's founder Wang Xingxing highlighted the current challenges in the robotics industry, particularly the difficulties in data collection and utilization, which hinder the effective deployment of AI models in robotics [2] - The robotics sector is facing a dual bottleneck of insufficient quality data and low utilization rates, alongside AI models that struggle with precise control, particularly in applications like dexterous hands [2] - Wang emphasized the need for the industry to focus on technological fundamentals, advocating for continued efforts in data accumulation and algorithm breakthroughs to bridge the gap between demonstration and practical application [2]

Core Insights - The research team at the Chinese Academy of Sciences has developed an engineered nanoenzyme that responds to deep red light or ultrasound, transforming proximity labeling technology into a powerful therapeutic tool [1][2] - The study, published in the journal Nature, demonstrates that artificially increasing antigen density on tumor cells can significantly enhance immune recognition and killing efficiency [1][2] Group 1 - The engineered nanoenzyme creates a strong artificial target on cancer cells, which allows for the effective aggregation of T cell receptors, triggering a potent attack mode against the targeted area [2] - In mouse experiments, the tumor volume was reduced by over 80%, and the immune system was activated to suppress untreated distant tumors, indicating a systemic anti-tumor effect [2] - Long-term studies show that cured mice exhibit complete immunity to secondary tumor challenges, suggesting the induction of long-lasting immune memory akin to vaccination against tumors [2] Group 2 - The research indicates that the new method significantly improves immune activation and killing efficiency compared to traditional antigen amplification methods [2] - The study's findings open new avenues for developing smarter and more efficient next-generation immunotherapies [2]

Macro News - The State Council has approved the launch of comprehensive reform pilot projects for market-oriented allocation of factors in 10 regions, including Beijing's sub-center and several key cities in Jiangsu and Zhejiang provinces, over the next two years [1][3] - Mexico plans to impose a 50% tariff on imports from China and other countries, with China's Ministry of Foreign Affairs expressing strong opposition to such measures [1][3] - The People's Bank of China and Bank Indonesia have initiated a bilateral currency settlement framework and QR code interoperability project, expected to be fully operational by 2025 [3] Industry News - A report from the Ministry of Natural Resources indicates that the Dadonggou gold mine in Liaoning Province has an estimated gold resource of nearly 1,500 tons, potentially becoming another world-class gold mine in China [4] - Morgan Stanley's latest report shows that U.S. investors' interest in the Chinese market has reached its highest level since 2021, maintaining high interest in both index investments and thematic opportunities [4] - Tesla's Model Y L is sold out for October, with expected delivery for new orders pushed to November [5] - The National Internet Information Office is actively addressing issues that disrupt the business network environment, targeting illegal online activities related to enterprises [5] - OPEC's monthly report indicates that the average oil production of OPEC+ in August was 42.4 million barrels per day, an increase of 509,000 barrels per day from July [6] - The Hangzhou government has released a charter to regulate the online delivery industry, promoting fair competition and prohibiting unfair practices [6] Company News - China Shipbuilding Industry Corporation has completed the share swap and absorption merger with China Shipbuilding Industry Group, with new shares listed on September 16 [8] - Chipone Technology announced plans to acquire shares of Chipone Technology, with a record high of 1.205 billion yuan in new orders signed from July 1 to September 11, of which 64% are related to AI computing power [8] - Transsion Holdings announced that shareholders plan to transfer 2% of the company's shares [9] - Jinpu Garden announced that shareholders plan to reduce their holdings by no more than 4.58% of the company's shares [10] - Youke Technology announced that the actual controller intends to transfer 5.13% of the company's shares at a price of 19.74 yuan per share [11] - Xinchun Technology stated that it maintains a good long-term cooperative relationship with Oracle [14]

Group 1 - The research team from the Chinese Academy of Sciences has developed a "nano-marking robot" that can accurately identify cancer cells, utilizing a chemical biology technique for disease treatment [1] - The "nano-marking robot" has shown promising efficacy in tumor models in mice and clinical tumor samples [1] - This research aims to pave the way for the development of smarter and more efficient next-generation immunotherapies for cancer [1] Group 2 - Alipay has launched the first domestic "AI payment" service, integrating the entire process of ordering and payment for intelligent agents [2] - This innovation allows users to place orders and make payments through voice commands, marking a significant advancement in payment methods in the AI era [2] - The service represents the first seamless integration of ordering and payment for intelligent agents, enhancing the AI service experience [2] Group 3 - Wang Xingxing, founder of Yushu Technology, highlighted the current challenges in the robotics industry, particularly regarding data quality and model capabilities [2] - The dual bottleneck of insufficient quality data and low utilization rates, along with the limitations of AI models, hinders the practical application of robotics [2] - The industry is at a critical juncture, with potential for explosive growth, but significant gaps remain between demonstration and practical usability [2]

Core Viewpoint - The research team led by Han Shuo from the Chinese Academy of Sciences has developed a "nano-marking robot" that can accurately identify cancer cells using engineered nanoenzymes responsive to deep red light or ultrasound, potentially paving the way for smarter and more efficient next-generation immunotherapies [1] Group 1: Research and Development - The team applied proximity labeling technology from chemical biology research to disease treatment [1] - The engineered nanoenzymes have shown good efficacy in both experimental mouse tumor models and in vitro clinical tumor samples [1] Group 2: Implications for Cancer Treatment - The development of this technology may open new avenues for the creation of advanced immunotherapies that can more effectively target cancer cells [1]